Lupin - Settles The U.S. Federal Antitrust Litigation For Glumetza’s Launch: Dolat Capital
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Lupin Ltd. has settled the U.S. federal antitrust litigation against direct purchaser and retailer groups at $250 million for Glumetza’s launch settlement.
Glumetza is an Extended Release form of Metformin HCL, approved by the food and drug administration in 2005, originally sold by Depomed (now Assertio). Depomed marketed the drug in partnership with Santarus, later acquired by Bausch.
In 2009, Lupin applied for generic version of Glumetza and in 2012, it settled with innovators to delay the product launch until 2016.
Against this settlement, Depomed agreed to pay Lupin’s legal fees and not launch its own AG until the company’s 180-day exclusivity is completed.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.